Twi Pharmaceuticals Inc., of Taipei, Taiwan, said its subsidiary, Twi Biotechnology Inc., gained FDA orphan drug status for AC-201, a drug it is developing for rare genetic connective tissue disorder epidermolysis bullosa, a pediatric disorder that leaves children with fragile skin that blisters and tears from friction or trauma.